Norinchukin Bank The Raises Stake in Eli Lilly and Co (LLY)

Norinchukin Bank The lifted its holdings in shares of Eli Lilly and Co (NYSE:LLY) by 3.2% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 123,121 shares of the company’s stock after purchasing an additional 3,786 shares during the quarter. Norinchukin Bank The’s holdings in Eli Lilly and were worth $10,532,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. raised its holdings in Eli Lilly and by 2.3% in the second quarter. Vanguard Group Inc. now owns 70,207,891 shares of the company’s stock valued at $5,778,109,000 after acquiring an additional 1,610,885 shares in the last quarter. BlackRock Inc. raised its holdings in Eli Lilly and by 2.1% in the second quarter. BlackRock Inc. now owns 63,583,747 shares of the company’s stock valued at $5,232,942,000 after acquiring an additional 1,323,259 shares in the last quarter. Janus Henderson Group PLC raised its holdings in Eli Lilly and by 7,093.5% in the second quarter. Janus Henderson Group PLC now owns 9,353,275 shares of the company’s stock valued at $769,774,000 after acquiring an additional 9,223,251 shares in the last quarter. Geode Capital Management LLC raised its holdings in Eli Lilly and by 8.4% in the first quarter. Geode Capital Management LLC now owns 9,103,975 shares of the company’s stock valued at $764,597,000 after acquiring an additional 708,597 shares in the last quarter. Finally, Janus Capital Management LLC raised its holdings in Eli Lilly and by 2.8% in the first quarter. Janus Capital Management LLC now owns 8,723,692 shares of the company’s stock valued at $733,731,000 after acquiring an additional 237,619 shares in the last quarter. 76.30% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Co (NYSE:LLY) opened at $85.07 on Friday. The company has a market cap of $94,264.75, a P/E ratio of 40.32, a price-to-earnings-growth ratio of 1.77 and a beta of 0.35. Eli Lilly and Co has a one year low of $72.68 and a one year high of $89.09. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.03 by $0.02. The company had revenue of $5.66 billion for the quarter, compared to analyst estimates of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The firm’s revenue was up 9.0% on a year-over-year basis. During the same period in the prior year, the firm posted $0.88 earnings per share. equities research analysts anticipate that Eli Lilly and Co will post 4.22 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be paid a $0.5625 dividend. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 annualized dividend and a yield of 2.64%. The ex-dividend date is Wednesday, February 14th. Eli Lilly and’s dividend payout ratio is currently 98.58%.

Several analysts recently weighed in on the stock. BMO Capital Markets set a $73.00 target price on shares of Eli Lilly and and gave the company a “sell” rating in a report on Tuesday, December 5th. Jefferies Group reaffirmed a “buy” rating and issued a $89.00 target price on shares of Eli Lilly and in a report on Thursday, August 31st. Leerink Swann raised their target price on shares of Eli Lilly and from $92.00 to $93.00 and gave the company a “market perform” rating in a report on Monday, October 23rd. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $105.00 target price (up previously from $103.00) on shares of Eli Lilly and in a report on Friday, September 8th. Finally, Credit Suisse Group reaffirmed a “hold” rating on shares of Eli Lilly and in a report on Wednesday, December 13th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have given a buy rating to the company. Eli Lilly and has a consensus rating of “Hold” and a consensus price target of $90.25.

In other news, SVP Alfonso G. Zulueta sold 2,003 shares of the firm’s stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $83.67, for a total transaction of $167,591.01. Following the transaction, the senior vice president now directly owns 43,580 shares in the company, valued at $3,646,338.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 195,000 shares of the firm’s stock in a transaction that occurred on Friday, September 29th. The stock was sold at an average price of $85.14, for a total transaction of $16,602,300.00. Following the transaction, the insider now owns 123,513,247 shares in the company, valued at $10,515,917,849.58. The disclosure for this sale can be found here. Insiders sold 651,088 shares of company stock worth $56,439,586 over the last quarter. 0.20% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION NOTICE: “Norinchukin Bank The Raises Stake in Eli Lilly and Co (LLY)” was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The correct version of this piece of content can be viewed at https://www.com-unik.info/2017/12/24/norinchukin-bank-the-raises-stake-in-eli-lilly-and-co-lly.html.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit